You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Alladapt’s allergy treatment receives FDA fast track designation

Alladapt Immunotherapeutics has announced that its investigational multi-food oral immunotherapy (mOIT), ADP101, has received Fast Track Designation from the US Food and Drug Administration (FDA).